We are live on ! Find out more
CRBP icon

Corbus Pharmaceuticals
CRBP

105 hedge funds and large institutions have $168M invested in Corbus Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 33 increasing their positions, 26 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

31% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 13

27% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 26

9% more capital invested

Capital invested by funds: $155M → $168M (+$13.5M)

2% more funds holding

Funds holding: 103 → 105 (+2)

0.05% less ownership

Funds ownership: 1.64% → 1.59% (-0.05%)

62% less call options, than puts

Call options by funds: $587K | Put options by funds: $1.54M

Holders
105
Holders Change
+2
Holders Change %
+1.94%
% of All Funds
2.07%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
17
Increased
33
Reduced
26
Closed
13
Calls
$587K
Puts
$1.54M
Net Calls
-$958K
Net Calls Change
-$23K

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.45M
2
JP Morgan Chase
JP Morgan Chase
New York
+$700K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$393K
4
GAI
General American Investors
New York
+$369K
5
California Public Employees Retirement System
California Public Employees Retirement System
California
+$339K

Top Sellers

Rank Fund Capital Flow
1
EMG
ETF Managers Group
New Jersey
-$5.47M
2
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
-$2.32M
3
SC
Sculptor Capital
New York
-$681K
4
AA
ALPS Advisors
Colorado
-$628K
5
Morgan Stanley
Morgan Stanley
New York
-$585K
Name Holding Trade Value Shares
Change 		Change in
Stake
ED
76
Exane Derivatives
France
$33.1K -$128K -865 -84%
AIP
77
Ameritas Investment Partners
Nebraska
$21K – – –
APA
78
American Portfolios Advisors
New York
$12.1K – – –
Rockefeller Capital Management
79
Rockefeller Capital Management
New York
$11K +$9.9K +67 New
LTFS
80
Ladenburg Thalmann Financial Services
Florida
$10K +$3.99K +27 +82%
VCP
81
Verus Capital Partners
Arizona
$10K +$9.31K +63 New
TIM
82
Tortoise Investment Management
New York
$8K +$7.39K +50 New
RIA
83
Realta Investment Advisors
Delaware
$7K – – –
SIM
84
Sonora Investment Management
Arizona
$7K – – –
HF
85
Halpern Financial
Virginia
$5.46K +$4.88K +33 New
HCM
86
Horrell Capital Management
Arkansas
$5K – – –
SFS
87
Sowell Financial Services
Arkansas
$5K – – –
CHA
88
Carmichael Hill & Associates
Maryland
$5K +$4.88K +33 New
MAWCM
89
Mine & Arao Wealth Creation & Management
California
$5K +$4.88K +33 New
TCWM
90
Total Clarity Wealth Management
Illinois
$4K +$3.25K +22 New
TRCT
91
Tower Research Capital (TRC)
New York
$2K -$17.9K -121 -90%
Daiwa Securities Group
92
Daiwa Securities Group
Japan
$2K – – –
SFPG
93
Stonebridge Financial Planning Group
Florida
$2K +$1.48K +10 New
AIS
94
Accurate Investment Solutions
Pennsylvania
$1K – – –
AF
95
Advisornet Financial
Minnesota
$1K – – –
APC
96
Aspire Private Capital
North Carolina
$1K – – –
EWM
97
Edge Wealth Management
New York
$1K – – –
TWA
98
TCI Wealth Advisors
Arizona
$1K – – –
TCM
99
Tradewinds Capital Management
Washington
$1K – – –
TC
100
Trust Company
Kansas
$1K – – –
1 2 3
4
5

CRBP Hedge Fund Activity: Q4 2019 in Review

105 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q4 2019, worth a combined $168M — up 8.7% from $155M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new CRBP positions and 13 closed out — a net gain of 4 holders — while 33 added to existing stakes and 26 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $1.45M. The largest seller was ETF Managers Group, cutting an estimated $5.47M.

  • 105 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q4 2019, up from 103 in Q3 2019.
  • Funds reported $168M of Corbus Pharmaceuticals stock for Q4 2019, up 8.7% quarter-over-quarter.
  • 17 funds opened new Corbus Pharmaceuticals positions in Q4 2019 and 13 closed out, a net change of +4 holders.
  • The largest Corbus Pharmaceuticals buyer in Q4 2019 was Susquehanna International Group, an estimated $1.45M added.
  • The largest Corbus Pharmaceuticals seller in Q4 2019 was ETF Managers Group, an estimated $5.47M sold.

Based on aggregated 13F filings for Q4 2019.